Broadcom Inc vs Revvity Inc — how do they compare? Broadcom Inc trades at $415.3 (market cap $1.98T), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Broadcom Inc is far larger — about 153.4× Revvity Inc's market cap, and Broadcom Inc pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| AVGO | RVTY | |
|---|---|---|
Market Cap | $1.98T | $12.91B |
Sector | Technology | Technology |
52-Week High | $481.57 | $117.75 |
52-Week Low | $289.60 | $82.26 |
Enterprise Value | $2.02T | $15.23B |
Dividend Yield | 0.62% | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Broadcom (AVGO) trades at $414.83, down 1.79% on the day, amid strong fundamentals including a 38.85% net income margin and consistent earnings beats. Technical analysis shows a bullish trend with key support at $412 and resistance at $422. The company reported robust cash flow from operations of $27.54 billion in 2025 and projects AI semiconductor revenue exceeding $100 billion by 2027, per CEO Hock Tan's reaffirmed forecast (The Motley Fool, 2026-08-11).
Outlook remains positive with 86% analyst buy ratings and a $510.21 consensus price target, though high valuation multiples (P/E 69.23) and competitive pressures in AI chips pose risks. The stock's growth is supported by booked AI revenue and strong cash generation, offering upside if execution continues.
RVTY trades at $117.88, up 1.6% today, with a bullish technical outlook and strong earnings momentum after beating Q2 2026 EPS estimates. The stock is near the consensus price target of $120.50, supported by a 51.72% analyst buy rating. Recent news highlights product launches like the SuperFlex prenatal system and investor conference participation, reinforcing growth prospects in diagnostics and biotech tools.
The outlook remains positive with revenue stability and margin strength, but elevated P/E of 55.64 poses valuation risk. Key opportunities include diagnostic demand and AI-driven workflows, while risks involve competitive pressures and execution challenges. Net cash flow turned positive in 2026, signaling improved financial health.
Trailing returns across standard periods
Latest headlines on both assets
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Read more on AVGO →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →